Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 139-140

  Osumi, T ^a   Miharu, M ^a   Tanaka, R ^a   Du, W ^a   Takahashi, T ^a   Shimada, H ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; IMATINIB; MESSENGER RNA; METHOTREXATE; PREDNISOLONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; BCR ABL GENE; BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CASE REPORT; CD3+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC PAIN; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FASCIITIS; FIBROTIC FASCIITIS; FUSION GENE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; INDUCTION CHEMOTHERAPY; JOINT LIMITATION; LETTER; LEUKEMIA REMISSION; LOCAL SKIN REACTION; MALE; MUSCLE TIGHTNESS; MYELOABLATIVE CONDITIONING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WHOLE BODY RADIATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; FASCIITIS; FIBROSIS; GRAFT VS HOST DISEASE; HUMANS; MALE; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855741230     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.10     Document Type: Letter

References (8)

1. Oda K, Nakaseko C, Ozawa S, Nishimura M, Saito Y, Yoshiba F et al. Fasciitis and myositis: an analysis of musclerelated complications caused by chronic GVHD after allo-SCT. Bone Marrow Transplant 2009; 43: 159-167.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
3. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316. (Pubitemid 40385302)
4. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al. Imatinib for refractory chronic graft-versushost disease with fibrotic features. Blood 2009; 114: 709-718.
5. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719-722.
6. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015. (Pubitemid 41741565)
7. Nakasone H, Kanda Y, Takasaki H, Nakaseko C, Sakura T, Fujisawa S et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 2010; 24: 1236-1239.
8. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-224.